Growth hormone pharmacogenetics: The interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and 202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency

Pharmacogenomics Journal

Volumn 12, Issue 5, 2012, Pages 439-445

  Costalonga, E F ^a   Antonini, S R R ^a   Guerra Junior, G ^b   Coletta, R R D ^a   Franca, M M ^a   Braz, A F ^a   Mendonca, B B ^a   Arnhold, I J P ^a   Jorge, A A L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

dwarfism; genetic variation; growth hormone deficiency; growth hormone therapeutic use; insulin like growth factor type 1; pharmacogenetics

Indexed keywords

ADENOSINE; CLONIDINE; CYTOSINE; GROWTH HORMONE RECEPTOR; INSULIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ALLELE; ARTICLE; CHILD; CORRELATION ANALYSIS; DISEASE SEVERITY; DNA POLYMORPHISM; EXON; FEMALE; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GHR GENE; GROWTH HORMONE DEFICIENCY; HOMOZYGOSITY; HUMAN; IGF1 GENE; IGFBP3 GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; TREATMENT OUTCOME;

CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MICROSATELLITE REPEATS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84866744024     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.13     Document Type: Article

References (36)

1. Stochholm K, Gravholt CH, Laursen T, Jorgensen JO, Laurberg P, Andersen M et al. Incidence of GH deficiency-a nationwide study. Eur J Endocrinol 2006; 155: 61-71.
2. Wit JM, Kamp GA, Rikken B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996; 39: 295-302.
3. GH Research Society. Consensus guidelines for the diagnosis treatment of growth hormone (GH) deficiency in childhood adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 2000; 85: 3990-3993.
4. Carel JC, Ecosse E, Nicolino M, Tauber M, Leger J, Cabrol S et al. Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. BMJ 2002; 325: 70.
5. Frisch H, Birnbacher R. Final height and pubertal development in children with growth hormone deficiency after long-term treatment. Horm Res 1995; 43: 132-134.
6. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999; 84: 1174-1183.
7. de Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction of adult height in growth-hormone-treated children with growth hormone deficiency. J Clin Endocrinol Metab 2007; 92: 925-931.
8. Geffner ME, Dunger DB. Future directions: growth prediction models. Horm Res 2007; 68(Suppl 5): 51-56.
9. Kristrom B, Wikland KA. Growth prediction models, concept and use. Horm Res 2002; 57(Suppl 2): 66-70.
10. Wit JM. Optimizing growth hormone therapy in growth hormone deficient children: what to do in the absence of hard evidence? Commentary on Rachmiel et al.: final height in children with idiopathic growth hormone deficiency treated with a fixed dose of recombinant growth hormone (Horm Res 2007;68:236-243). Horm Res 2007; 68: 244-247.
11. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 2006; 91: 1076-1080.
12. Jorge AA, Arnhold IJ. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment. Horm Res 2009; 71(Suppl 2): 55-63.
13. Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab 2009; 94: 3721-3730.
14. Costalonga EF, Antonini SR, Guerra-Junior G, Mendonca BB, Arnhold IJ, Jorge AA. The 202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency. J Clin Endocrinol Metab 2009; 94: 588-595.
15. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30: 494-535.
16. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996; 98: 2612-2615.
17. Li HJ, Ji CY, Wang W, Hu YH. A twin study for serum leptin, soluble leptin receptor, and free insulin-like growth factor-I in pubertal females. J Clin Endocrinol Metab 2005; 90: 3659-3664.
18. Ester WA, Hokken-Koelega AC. Polymorphisms in the IGF1 and IGF1R genes and children born small for gestational age: results of large population studies. Best Pract Res Clin Endocrinol Metab 2008; 22: 415-431.
19. Frayling TM, Hattersley AT, McCarthy A, Holly J, Mitchell SM, Gloyn AL et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in UK Populations. Diabetes 2002; 51: 2313-2316.
20. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83: 2286-2290.
21. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989; 44: 388-396.
22. Silva EG, Slhessarenko N, Arnhold IJ, Batista MC, Estefan V, Osorio MG et al. GH values after clonidine stimulation measured by immunofluorometric assay in normal prepubertal children and GH-deficient patients. Horm Res 2003; 59: 229-233.
23. Rocha MG, Marchisotti FG, Osorio MG, Marui S, Carvalho LR, Jorge AA et al. High prevalence of pituitary magnetic resonance abnormalities and gene mutations in a cohort of Brazilian children with growth hormone deficiency and response to treatment. J Pediatr Endocrinol Metab 2008; 21: 673-680.
24. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child 1966; 41: 613-635.
25. Greulich WW, Pylc SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. Stanford University Press: Palo Alto, CA, 1959.
26. Arends N, Johnston L, Hokken-Koelega A, van Duijn C, de Ridder M, Savage M et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 2002; 87: 2720.
27. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001; 50: 637-642.
28. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 2000; 275: 18664-18669.
29. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10: 377-384.
30. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, Lamberts SW. A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol 2003; 148: 171-175.
31. Cordell HJ. Genome-wide association studies: detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10: 392-404.
32. Li W, Reich J. A complete enumeration and classification of two-locus disease models. Hum Hered 2000; 50: 334-349.
33. van der Kaay DC, Hendriks AE, Ester WA, Leunissen RW, Willemsen RH, de Kort SW et al. Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age. Growth Horm IGF Res 2009; 19: 198-205.
34. Clemmons DR. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res 2001; 55(Suppl 2): 73-79.
35. Marchini J, Donnelly P, Cardon LR. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet 2005; 37: 413-417.
36. Lettre G, Butler JL, Ardlie KG, Hirschhorn JN. Common genetic variation in eight genes of the GH/IGF1 axis does not contribute to adult height variation. Hum Genet 2007; 122: 129-139.